wiki pageCreated: 2026-04-02T07:19:08By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-proteins-ciita-protein
📖 Wiki Page
protein722 wordssynced 2026-04-02
CIITA Protein
<div class="infobox infobox-protein"> | | | |---|---| | Protein Name | CIITA Protein | | Gene | [CIITA](/genes/ciita) | | UniProt ID | [P33076](https://www.uniprot.org/uniprot/P33076) | | Alternative Names | Class II Major Histocompatibility Complex Transactivator, CIITA | | Molecular Weight | ~125 kDa | | Structure | N-terminal acidic domain, proline/serine/threonine-rich region, LRR repeat region | | Subcellular Localization | Nucleus | </div>
Overview
CIITA (Class II Major Histocompatibility Complex Transactivator) is a critical transcriptional coactivator that serves as the master regulator of MHC class II gene expression[@mach1996]. Originally characterized for its essential role in antigen presentation to CD4+ T cells, CIITA has emerged as an important player in neuroimmune interactions relevant to neurodegenerative diseases[@wistar2004].
Molecular Function
Transcriptional Coactivator Activity
CIITA does not directly bind DNA but functions as a transcriptional coactivator by recruiting chromatin remodelers and general transcription factors to MHC class II promoters. Its structure includes:
N-terminal acidic domain: Mediates interactions with transcriptional coactivators like CBP/p300
Proline/serine/threonine-rich region: Contains phosphorylation sites that regulate its activity
Leucine-rich repeat (LRR) region: Involved in protein-protein interactions and nuclear localization
MHC Class II Regulation
...
CIITA Protein
<div class="infobox infobox-protein"> | | | |---|---| | Protein Name | CIITA Protein | | Gene | [CIITA](/genes/ciita) | | UniProt ID | [P33076](https://www.uniprot.org/uniprot/P33076) | | Alternative Names | Class II Major Histocompatibility Complex Transactivator, CIITA | | Molecular Weight | ~125 kDa | | Structure | N-terminal acidic domain, proline/serine/threonine-rich region, LRR repeat region | | Subcellular Localization | Nucleus | </div>
Overview
CIITA (Class II Major Histocompatibility Complex Transactivator) is a critical transcriptional coactivator that serves as the master regulator of MHC class II gene expression[@mach1996]. Originally characterized for its essential role in antigen presentation to CD4+ T cells, CIITA has emerged as an important player in neuroimmune interactions relevant to neurodegenerative diseases[@wistar2004].
Molecular Function
Transcriptional Coactivator Activity
CIITA does not directly bind DNA but functions as a transcriptional coactivator by recruiting chromatin remodelers and general transcription factors to MHC class II promoters. Its structure includes:
N-terminal acidic domain: Mediates interactions with transcriptional coactivators like CBP/p300
Proline/serine/threonine-rich region: Contains phosphorylation sites that regulate its activity
Leucine-rich repeat (LRR) region: Involved in protein-protein interactions and nuclear localization
MHC Class II Regulation
CIITA is essential for the expression of all MHC class II genes (HLA-DP, HLA-DQ, HLA-DR) by recruiting the transcriptional machinery including RFX5, RFXAP, and RFXANK to the promoters[@mach1996]. This function is critical for professional antigen-presenting cells (dendritic cells, B cells, macrophages).
Role in Neurodegenerative Diseases
Alzheimer's Disease
In Alzheimer's disease (AD), CIITA plays a complex role in neuroinflammation and immune responses:
Microglial Activation: CIITA expression in [microglia](/cell-types/microglia-neuroinflammation) regulates MHC class II presentation, influencing the inflammatory milieu around [amyloid-beta](/proteins/amyloid-beta) plaques[@wistar2004]. The chronic inflammatory response in AD involves dysregulated CIITA-mediated antigen presentation.
Adaptive Immunity: MHC class II expression on antigen-presenting cells in the brain enables presentation of neural antigens to infiltrating T cells, potentially modulating neuroinflammation[@michaelson2017].
Therapeutic Implications: Modulating CIITA activity represents a potential approach to fine-tune neuroinflammatory responses in AD, though this remains experimental.
Parkinson's Disease
In Parkinson's disease (PD), CIITA-mediated immune responses contribute to dopaminergic neuron degeneration:
[α-Synuclein](/proteins/alpha-synuclein) Immunity: CIITA regulates MHC class II expression on microglia that can present α-synuclein epitopes, potentially triggering adaptive immune responses[@sulzer2017].
Neuroinflammation: The progressive loss of dopaminergic [neurons](/entities/neurons) in the substantia nigra is accompanied by chronic neuroinflammation involving CIITA-expressing immune cells.
Therapeutic Targeting: Strategies targeting CIITA-mediated antigen presentation may modulate the neuroimmune axis in PD.
Amyotrophic Lateral Sclerosis
CIITA involvement in ALS includes:
T Cell-Mediated Immunity: In ALS, CIITA-regulated MHC class II expression influences the interaction between motor neurons and immune cells[@pagano2022].
Glial Cell Activation: [Astrocytes](/entities/astrocytes) and microglia expressing MHC class II via CIITA may contribute to motor neuron injury.
Neuroinflammation: The inflammatory environment in ALS involves CIITA-mediated antigen presentation pathways.
Signaling Pathways
CIITA integrates with several signaling pathways:
IFN-γ Signaling: CIITA is strongly induced by interferon-gamma, which is elevated in neurodegenerative disease contexts[@wistar2004]
JAK-STAT Pathway: STAT1 activation leads to CIITA transcription
[NF-κB](/entities/nf-kb) Pathway: Cross-talk between CIITA and NF-κB signaling modulates inflammatory responses
Therapeutic Targeting
CIITA represents a potential therapeutic target for neurodegenerative diseases:
Immunomodulation: Modulating CIITA activity could fine-tune beneficial vs. harmful neuroinflammatory responses
[Unknown, Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annual Review of Immunology. 1996 (1996)](https://pubmed.ncbi.nlm.nih.gov/8717518/)
[Wistar R, et al., MHC class II expression in Alzheimer's disease brain. Journal of Neuroimmunology. 2004 (2004)](https://pubmed.ncbi.nlm.nih.gov/15589623/)
[Michaelson JS, et al., CIITA and adaptive immunity in neurodegeneration. Journal of Alzheimer's Disease. 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28671194/)
[Sulzer D, et al., T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature. 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28514433/)
[Pagano J, et al., Immune dysregulation in amyotrophic lateral sclerosis. Brain. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35036942/)